Innoviz Technologies’ founding team, which includes CEO Omer Keilaf, CBO Oren Rosenzweig and Chief R&D Officer Oren Buskila.
Innoviz Technologies, an Israeli provider of high-performance, automotive-grade LiDAR sensors and perception software, and Novocure, an Israeli medtech company that develops and sells a treatment using electric fields for various types of cancer, both successes this past week. For Novocure, it was in a trial for the company’s LUNAR study.
Novocure LUNAR study met its primary endpoint, said the company, demonstrating a “statistically significant and clinically meaningful improvement in overall survival over standard therapies alone.” The company declared the LUNAR study to be a pivotal, open-label, randomized study evaluating the safety and efficacy of Tumor Treating Fields (TTFields) together with standard therapies for stage 4 non-small cell lung cancer (NSCLC) following progression while on or after treatment with platinum-based therapy.
The LUNAR study also showed a statistically significant and clinically meaningful improvement in overall survival when patients were treated with TTFields and immune checkpoint inhibitors (ICI), as compared to those treated with immune checkpoint inhibitors alone, and a positive trend in overall survival when patients were treated with TTFields and docetaxel versus docetaxel alone.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at [email protected].
Thank you.
Founded in 2000, Novocure is an oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure’s commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma and malignant pleural mesothelioma. Novocure has ongoing or completed clinical studies investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.
“We are pleased with the positive readout of the LUNAR study. Prior to LUNAR, the last phase 3 trial to lead to significant improvement in overall survival in late-stage, platinum-resistant non-small cell lung cancer was six years ago, underlining the difficulty in treating this disease,” said William Doyle, Novocure’s Executive Chairman. “We are also pleased by the profound performance of the TTFields together with immunotherapy, which has the potential to meaningfully extend patient survival beyond what was previously possible.”
As for Innoviz, the company unveiled Innoviz360, the newest member of the high-performance Innoviz LiDAR family. The company states that Innoviz360 offers an “improved performance with substantial cost reduction. The Innoviz360 innovative design is based on a new approach that overcomes existing spinning LiDAR barriers that are limited in performance, expensive, and too large for most applications.”
Lidar is a component of Advanced Driver Assistance System (ADAS). Lidar measures distances by illuminating a target with laser light and measuring the reflection with a sensor. Differences in laser return times and wavelengths can then be used to make digital 3-D representations of the target. And a number of Israeli firms work in the field.
For example, last week Opsys Tech Ltd., an Israeli startup that develops a patented True Solid-State Scanning LiDAR technology, held the final closing of its Series C financing round. The final closing raised $36.5 million, bringing the total amount of the company’s Series C funding to $51.5 million. And the most prominent and successful Israeli company that works in the field is of course Mobileye, which offers autonomous driving and driver-assist technologies. In October Mobileye hit a $17 billion valuation with a NASDAQ IPO.
Founded in 2016 by Israeli Intelligence Corps veterans from Unit 81 Oren Rosenzweig and Omer David Keilaf, Innoviz produces solid-state LiDAR sensors and perception software that enable the mass-production of autonomous vehicles. Its solutions include InnovizPro and InnovizOne which provides 3D sensing for Level 3-Level 5 autonomous driving.
“Innoviz continues to show its commitment to break through meaningful technology barriers that allow safety in mobility,” said Omer Keilaf, Co-Founder and CEO of Innoviz. “The Innoviz360 adds another dimension to the company’s growth by enabling Innoviz to become a one-stop shop for all types of LiDAR solutions”
